New report on CEL-SCI's H1N1 flu drug candidate

Editorial Checklist Reviewed
Sep 24 2009NewsGuard 100/100 Score

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published a new report about CEL-SCI Corporation's (NYSE Amex: CVM) new H1N1 flu drug candidate.

Hype versus substance. Perception versus reality. During the past week, there has been much debate regarding the work being done by CEL-SCI in the pandemic influenza space, but previously published data may help shed new light on the L.E.A.P.S platform which is being used to develop the treatment.

Are there applications for CEL-SCI's work beyond the scope and urgency of the current pandemic that may open up other lucrative markets?

The new article can be read in their entirety at BioMedReports.Com:

Source:

http://biomedreports.com/component/content/article/56-top-leading-news/10621-intriguing-revelations-deciphering-cel-scis-h1n1-flu-play.html

Posted in: Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

H5N1 bird flu is mutating fast and jumping to mammals - could the next pandemic be here?
Macrophage memory following COVID infection provides cross-virus protection
As California taps pandemic stockpile for bird flu, officials keep close eye on spending
Exclusive: Emails reveal how health departments struggle to track human cases of bird flu
New CDC report highlights disparities in flu hospitalization and vaccination
New insights into how IFITM3 protein protects against severe flu
Electronic nudges improve flu vaccination rates in non-diabetic patients but fail to increase uptake in diabetics
Study reveals high effectiveness of flu vaccines in children but highlights challenges with certain subtypes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Electronic nudges boost flu vaccination rates among heart attack survivors